Bronstein, Gewirtz & Grossman, LLC announced that a securities class action has been filed against Ardelyx, Inc. (NASDAQ: ARDX) and certain officers on behalf of investors who acquired Ardelyx securities from January 13, 2025 through August 6, 2026. The complaint alleges that the company failed to disclose growing payer-related access and reimbursement obstacles for XPHOZAH and IBSRELA, including stricter prior-authorization and step-edit requirements that allegedly impeded patient starts and prescription fulfillment. Investors who suffered losses have until November 16, 2026 to seek appointment as lead plaintiff. The Ardelyx notice is a separate matter from previously reported securities class-action notices involving Flotek Industries, AEVEX Corp. and Aardvark Therapeutics.